NeoGenomics Inc. (NEO)
NASDAQ: NEO
· Real-Time Price · USD
9.04
0.06 (0.67%)
At close: Oct 03, 2025, 2:30 PM
0.67% (1D)
| Bid | 6.56 |
| Market Cap | 230.28M |
| Revenue (ttm) | 689.19M |
| Net Income (ttm) | -104.04M |
| EPS (ttm) | -0.82 |
| PE Ratio (ttm) | -11.02 |
| Forward PE | 48.42 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 11.35 |
| Volume | 2,689,950 |
| Avg. Volume (20D) | 2,645,455 |
| Open | 9.00 |
| Previous Close | 8.98 |
| Day's Range | 8.82 - 9.17 |
| 52-Week Range | 4.72 - 19.11 |
| Beta | 1.61 |
| Ex-Dividend Date | n/a |
Analyst Forecast
According to 0 analyst ratings, the average rating for NEO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNeoGenomics Inc. is scheduled to release its earnings on
Nov 4, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+21.78%
NeoGenomics shares are trading higher after the co...
Unlock content with
Pro Subscription
2 months ago
-18.73%
NeoGenomics shares are trading lower after the company reported a Q2 revenue miss and cut its FY25 sales guidance below estimates.
2 months ago · businesswire.com
NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid BiopsyFORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company's PanTracer portfolio.
